A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting by Bruyère, Olivier et al.
Seminars in Arthritis and Rheumatism 45 (2016) S3–S11Contents lists available at ScienceDirectSeminars in Arthritis and Rheumatismhttp://d
0049-01
(http://c
Abbre
articula
SYSADO
n Corr
E-mjournal homepage: www.elsevier.com/locate/semarthritA consensus statement on the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
algorithm for the management of knee osteoarthritis—From
evidence-based medicine to the real-life setting
Olivier Bruyère, PhDa,n, Cyrus Cooper, MD, PhDb,c, Jean-Pierre Pelletier, MDd,
Emmanuel Maheu, MDe, François Rannou, MD, PhDf, Jaime Branco, MDg,
Maria Luisa Brandi, MDh, John A. Kanis, MDi, Roy D. Altman, MDj,
Marc C. Hochberg, MD, PhDk,l,m, Johanne Martel-Pelletier, PhDd,
Jean-Yves Reginster, MD, PhDn
a Support Unit in Epidemiology and Biostatistics, Department of Public Health, Epidemiology and Health Economics, University of Liège,
CHU Sart Tilman, Liège 4000, Belgium
b MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
c NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
d Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada
e Rheumatology Department, AP-HP, Saint-Antoine Hôpital, Paris, France
f Rehabilitation Unit, Rheumatology Department, Hôpital Cochin, AP-HP, INSERM UMR-S 1124, Université Paris Descartes, Paris, France
g CEDOC, Department of Rheumatology, Faculdade de Ciências Médicas, Universidade Nova de Lisboa/CHLO, EPE–Hospital Egas Moniz, Lisbon, Portugal
h Department of Internal Medicine, University of Florence, Florence, Italy
i WHO Collaborating Centre for Metabolic Bone Diseases, University of Shefﬁeld, Shefﬁeld, UK
j David Geffen School of Medicine, University of California, Los Angeles, CA
k Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
l Geriatric Research, Education and Clinical Center, Baltimore, MD
m Health Care System, Baltimore, MD
n Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgiuma r t i c l e i n f o
Keywords:
Glucosamine
Chondroitin
Hyaluronic acid
Knee osteoarthritis
Non-steroidal anti-inﬂammatory drugs
Symptomatic slow-acting drugs for
osteoarthritis (SYSADOAs)
Tramadolx.doi.org/10.1016/j.semarthrit.2015.11.010
72/& 2015 The Authors. Published by Elsevie
reativecommons.org/licenses/by-nc-nd/4.0/).
viations: CS, chondroitin 4&6 sulfate; GS, gl
r; HA, hyaluronic acid; pCGS, patented cry
As, symptomatic slow-acting drugs for osteoa
esponding author.
ail address: olivier.bruyere@ulg.ac.be (O. Bruya b s t r a c t
The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
published a treatment algorithm for the management of knee osteoarthritis (OA) in 2014, which provides
practical guidance for the prioritization of interventions. Further analysis of real-world data for OA
provides additional evidence in support of pharmacological interventions, in terms of management of OA
pain and function, avoidance of adverse events, disease-modifying effects and long-term outcomes, e.g.,
delay of total joint replacement surgery, and pharmacoeconomic factors such as reduction in healthcare
resource utilization. This article provides an updated assessment of the literature for selected
interventions in OA, focusing on real-life data, with the aim of providing easy-to-follow advice on
how to establish a treatment ﬂow in patients with knee OA in primary care clinical practice, in support of
the clinicians’ individualized assessment of the patient. In step 1, background maintenance therapy with
symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) is recommended, for which high-quality
evidence is provided only for the prescription formulations of patented crystalline glucosamine sulfate
and chondroitin sulfate. Paracetamol may be added for rescue analgesia only, due to limited efﬁcacy and
increasing safety signals. Topical non-steroidal anti-inﬂammatory drugs (NSAIDs) may provide additional
symptomatic treatment with the same degree of efﬁcacy as oral NSAIDs without the systemic safety
concerns. Oral NSAIDs maintain a central role in step 2 advanced management of persistent symptoms.
However, oral NSAIDs are highly heterogeneous in terms of gastrointestinal and cardiovascular safety
proﬁle, and patient stratiﬁcation with careful treatment selection is advocated to maximize the risk:r HS Journals, Inc. This is an open access article under the CC BY-NC-ND license
ucosamine sulfate; IA, intra-
stalline glucosamine sulfate;
rthritis.
ère).
O. Bruyère et al. / Seminars in Arthritis and Rheumatism 45 (2016) S3–S11S4beneﬁt ratio. Intra-articular hyaluronic acid as a next step provides sustained clinical beneﬁt with effects
lasting up to 6 months after a short-course of weekly injections. As a last step before surgery, the slow
titration of sustained-release tramadol, a weak opioid, affords sustained analgesia with improved
tolerability.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis (OA) is a progressive disease of the synovial
joints that causes joint pain and limitation of function resulting
in considerable morbidity, impairment of quality of life, and social
and economic burden [1,2]. Knee OA is the most common OA
localization, and symptomatic knee OA is highly prevalent among
people aged over 50 years, affecting more than 250 million people
worldwide [3]. OA accounts for a substantial number of healthcare
consultations and is a leading indication for use of prescription
drugs, at around US $3000 per patient per year [4]. With the
increasing aging population, OA is expected to become the fourth
leading cause of disability by 2020 [1]. The goals of treatment for
OA are to reduce symptoms and ultimately slow disease progres-
sion, which may in turn reduce the impact of OA on the patient's
mobility and quality of life, and lead to a reduction in the need for
rescue analgesia and joint replacement surgery in the long term,
with consequent reduction in healthcare resource needs.
In 2014, the European Society for Clinical and Economic Aspects
of Osteoporosis and Osteoarthritis (ESCEO) published a treatment
algorithm for the management of knee OA, which provides
practical guidance for the prioritization of interventions and
guides physicians through progressive, logical steps [5]. This
represents a signiﬁcant advance in the preparation of recommen-
dations for the treatment of OA, where previous guideline devel-
opment has analyzed the level of evidence behind each
intervention without prioritizing the interventions in a given
sequence [6–9]. The ESCEO algorithm was developed by an
international task force through analysis of the clinical trial
evidence related to OA and detailed discussion to develop the
algorithm. This article provides an updated assessment of the
literature for selected interventions in OA, with particular focus on
real-life data, with the aim of providing further practical guidance
on the management of OA patients in primary care clinical
practice, as was discussed at a meeting of the ESCEO task force
in May 2015. Non-pharmacological background treatments were
extensively reviewed previously and are not further examined
here [5]. Pharmacological interventions for OA are discussed in
some detail, and a simpliﬁed algorithm for the pharmacological
management of OA has been developed by the ESCEO task force,
which is presented here (Fig.). Further analysis of the evidence base
in support of the interventions discussed here is provided in the four
accompanying review articles included in this issue [10–13].Step 1: Pharmacological treatment
Paracetamol
Paracetamol is widely recommended as a ﬁrst-line step for
rescue analgesia, despite the fact that the effect of paracetamol on
symptoms is minimal [5–9], with only a small effect size (ES) on
pain at 0.14 [95% conﬁdence interval (CI): 0.05–0.22] and no
signiﬁcant effect on stiffness and physical function in patients
with knee OA [14]. The persistent use of paracetamol, particularly
in primary care, is largely due to the presumed safety of para-
cetamol and low cost. However, recent concerns over the safety
proﬁle of paracetamol raise questions over its routine, chronic use.Evidence is accumulating for an increased risk of upper gastro-
intestinal (GI) events with paracetamol use, and elevated risk of
severe liver injury with high daily doses [15]. Treatment with
high-dose paracetamol (43 g/day) is associated with a greater
risk of hospitalization due to GI perforation, ulceration, or bleeding
(PUB) than lower daily doses of paracetamol [hazard ratio (HR) ¼
1.20; 95% CI: 1.03–1.40] [16]. There is also evidence for loss of renal
function in women following long-term consumption of high
doses of paracetamol (43 g/day) [odds ratio (OR) ¼ 2.04; 95%
CI: 1.28–3.24], with a decline in glomerular ﬁltration rate
(GFR) 430 ml/min, and increase in hypertension in men [relative
risk (RR) ¼ 1.34; 95% CI: 1.00–1.79] and women (RR ¼ 2.00; 95%
CI 1.52–2.62) [17–19].
In primary care, paracetamol may still be used to treat pain in
mild-moderate OA at daily doses up to 3 g/day. However, if
paracetamol is ineffective or insufﬁciently effective, the physician
should consider stopping and switching treatment, or adding-on
other therapies.
SYSADOAs
A preferential approach to Step 1 treatment of knee OA
recommended by the ESCEO task force is to initiate background
therapy with chronic symptomatic slow-acting drugs for osteo-
arthritis (SYSADOAs), with the addition of paracetamol as short-
term rescue analgesia as needed (Fig.) [5]. Among SYSADOAs, the
evidence is greatest for the effect of prescription-grade glucos-
amine sulfate (GS) and chondroitin 4&6 sulfate (CS). Other SYSA-
DOAs, including diacerein, avocado-soybean unsaponiﬁable (ASU),
collagen fragments, or plants extracts have been suggested as
potential treatments for OA. Data from preclinical studies provide
evidence that diacerein may impact abnormal articular tissue
metabolism in OA [20]. Clinical evidence suggests that diacerein
might have structure-modifying effects in hip OA [21], which
provides a basis for further research particularly in knee OA that
is lacking. For the other putative SYSADOAs, the evidence for any
preclinical or clinical effect is limited [22].
Glucosamine sulfate
A large amount of trials have investigated the efﬁcacy of GS in
the management of OA symptoms and potential disease-modifying
effects through the delay of joint structural changes [23–27].
Numerous formulations of glucosamine as both sulfate and hydro-
chloride (HCl) salts are available as prescription-only, generic,
over-the-counter (OTC) products and dietary supplements. How-
ever, it is apparent from careful consideration of the evidence base
that only the patented crystalline glucosamine sulfate (pCGS)
formulation (Rottapharm) [28] has proven efﬁcacy in the treat-
ment of OA [23–25]. A Cochrane review of randomized controlled
trials (RCTs) concluded “only those studies evaluating the Rotta
preparation showed that glucosamine was superior to placebo in
the treatment of pain and functional impairment”. In fact, when
this meta-analysis was restricted to studies with adequate con-
cealment it failed to show any beneﬁt of glucosamine for pain
[standardized mean difference (SMD) ¼ 0.16; 95% CI: 0.36 to
0.04] [23]. This ﬁnding was reﬂected in an analysis of only those
RCTs employing any non-Rottapharm preparation of glucosamine,
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(SMD ¼ 0.05; 95% CI: 0.15 to 0.05). Notably, when the RCTs
using the pCGS formulation (“Rotta preparation” in the Cochrane
review) were analyzed separately, pCGS was found to be superior
for pain (SMD ¼ 1.11; 95% CI: 1.66 to 0.57) and function
(Lesquesne index SMD ¼ 0.47; 95% CI: 0.82 to 0.12), albeit
with high heterogeneity between trials (I2 ¼ 92%) [23]. To overcome
the issue of heterogeneity, one may look only at the three pivotal
trials of pCGS [26,27,29], which have been independently assessed
as of the highest quality (Jadad score ¼ 5) and with “low risk of
bias” [24,25], thus falling within the studies with adequate conceal-
ment in the Cochrane review [23]. These studies have assessed the
efﬁcacy of pCGS on OA symptom management and functional
outcomes for 6 months up to 3 years [26,27,29]. In independent
meta-analyses, the calculated global effect size (ES) of pCGS on pain
was 0.27 (95% CI: 0.12–0.43) without heterogeneity [24,25].
Although this effect size was moderate, it is greater than the effect
of paracetamol (ES ¼ 0.14), as conﬁrmed in a head-to-head study
[29], and similar to the effect size measured for non-steroidal anti-
inﬂammatory drugs (NSAIDs) (ES ¼ 0.32; 95% CI: 0.24–0.39) [14,30].
In addition, a signiﬁcant effect on function for pCGS was demon-
strated with an effect size of 0.33 (95% CI: 0.17–0.48) for Western
Ontario McMaster Universities Osteoarthritis Index (WOMAC) func-
tion and 0.38 (95% CI: 0.18–0.57) for Lesquesne index [24].
The further beneﬁt of chronic administration of pCGS is shown
by long-term studies that demonstrate a signiﬁcant reduction in
joint space narrowing (JSN) as compared with placebo over 3 years
of treatment [26,27]. Radiographic JSN of 40.5 mm over 2–3
years is considered a reliable surrogate measure for total jointreplacement (TJR) [31]: the proportion of patients with JSN of
40.5 mm was signiﬁcantly reduced in both pCGS pivotal 3-year
trials [26,27]. The evidence for long-lasting disease-modifying effects
of pCGS is further borne out by the real-life follow up of patients
included in these long-term RCTs [32]. Treatment with pCGS for
at least 12 months signiﬁcantly delayed the need for TJR surgery
(p ¼ 0.026); TJR occurred in twice as many patients from the
placebo group in the 5 years of follow-up compared with those
patients who had received pCGS (RR ¼ 0.43; 95% CI: 0.20–0.92) [32].
The pharmacoeconomic beneﬁts of long-term pCGS are dem-
onstrated in real-life studies showing a reduction in need for
concomitant NSAID use of 36–50% [32,33], and in reduction of the
utilization of healthcare resources, including physician visits and
examinations [32]. Further, cost-effectiveness analysis of a 6-
month treatment trial using the incremental cost-effectiveness
ratio (ICER) has shown pCGS to be a highly cost-effective therapy
compared with paracetamol and placebo to treat patients with
primary knee OA [29,34].
The ESCEO task force advocates the differentiation of prescription
pCGS from other glucosamine preparations as a ﬁrst-line SYSADOA
for medium- to long-term control of knee OA symptoms (Fig.). Only
pCGS is given as a highly bioavailable once-daily dose (1500 mg) with
a proven pharmacological effect [35] that equates to a clear clinical
beneﬁt in trials and real-life studies of knee OA.
Chondroitin sulfate and SYSADOA combinations
Studies using prescription-grade CS have shown that CS may
offer similar beneﬁts on joint structure changes in patients with
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reportedly variable [8]; although more recent studies and system-
atic reviews show that prescription-grade CS has an effect on joint
structural changes that could be clinically relevant, with efﬁcacy
on symptoms of the disease that could be of similar magnitude to
that of GS [38–40].
Glucosamine and CS are often used in combination as dietary
supplements, which raises the question of whether there is any
additional beneﬁt derived from the combination. However, there are
currently no trials of the combination of the two pharmaceutical-
grade prescription preparations of CS and GS (as pCGS) compared
with CS or pCGS alone, or to a comparator or placebo, to address this
question. In the Glucosamine/Chondroitin Arthritis Intervention
Trial (GAIT), although glucosamine hydrochloride (GH) or CS alone
or in combination did not reduce pain effectively in the overall
group of patients with knee OA, a positive trend for a symptomatic
effect of the combination of CS plus GH was shown in the subgroup
of patients with moderate-to-severe knee pain [41]. Moreover, the
combination of pharmaceutical-grade CS plus GH is reported to
provide an effect non-inferior to that of celecoxib [42], albeit in the
absence of a placebo comparison. Since GH is demonstrated to
provide an effect equivalent to that of placebo on symptomatic and
structural management of OA [41,43] and its combination with CS
decreases glucosamine bioavailability by 50–75% [35], any beneﬁt of
the combination of CS and GH is difﬁcult to interpret and may be
mainly attributable to CS.
Evidence for a disease-modifying effect of the combination is
shown in a recent trial of once-daily non-prescription-grade GS
(1500 mg) and CS (800 mg) which found a statistically signiﬁcant
reduction in JSN at 2 years compared with placebo (mean differ-
ence 0.10 mm; 95% CI: 0.002–0.20 mm; p ¼ 0.046) [44]. Another
study using the Osteoarthritis Initiative (OAI) cohort found a
reduced loss of cartilage volume over 2 years with dietary supple-
ment combinations of glucosamine and CS [45]. These data are in
line with the earlier and stronger evidence for a disease-modifying
effect of pCGS alone [26,27,32] or, pharmaceutical-grade CS alone
[36–38]. Thus, there is limited evidence to suggest that combina-
tions of non-prescription-grade glucosamine (including GH) and
chondroitin should be preferred to either of the two single,
pharmaceutical-grade prescription agents. Conversely, since both
pCGS and CS are considered as safe medications, with no differ-
ence in adverse events (AEs) compared with placebo [23,38], and
both are associated with long-term symptom-modifying effects
[24,25,40], protection of joint cartilage and delay in disease
progression [46], it may be wise to perform placebo-controlled
RCTs to conﬁrm the clinical beneﬁt of the combination of the two
prescription-grade agents beyond monotherapies alone.
Topical NSAIDs
Topical NSAIDs may be added to the treatment regimen if the
patient is still symptomatic after establishing appropriate back-
ground pharmacological therapy with SYSADOAs, and rescue
analgesia with paracetamol provides insufﬁcient symptom relief.
The efﬁcacy of topical NSAIDs in knee OA has been established in
RCTs and meta-analyses [47–50]. Evidence from head-to-head
studies show that topical NSAIDs are as effective as oral NSAIDs,
but with a lower risk for gastrointestinal (GI) AEs albeit with an
increased risk of mild skin reactions [47]. The pooled effect size for
pain relief with topical NSAIDs was calculated as 0.44 (95% CI:
0.27–0.62), although there is a heterogeneity of efﬁcacy between
products (I2 ¼ 69%) [48]. Data for topical diclofenac showed the
number needed to treat (NNT) for at least 50% pain relief over 8–12
weeks as six for the solution and 11 for the gel formulation [51].
However, recent studies of topical ketoprofen failed to demon-
strate a beneﬁt of treatment over placebo [52,53]. Good absorptionthrough the skin and accumulation of the active agent in the target
tissues are important factors, which contribute to the efﬁcacy of
topical NSAIDs, alongside low plasma levels to minimize systemic
AEs and improve tolerability. The bioavailability of topical NSAID
formulations varies, with etofenamate demonstrating the highest
bioavailability at 21% [54], and accumulation in inﬂamed target
tissues at levels 10-times that of the plasma concentration [55].
Topical diclofenac has also been shown to accumulate in the
synovial tissue [56].
In real-life studies, topical NSAIDs demonstrated an equivalent
effect on knee pain to oral NSAIDs over 1 year of treatment, with
fewer AEs reported with topical NSAIDs [57]. In addition, the use of
topical NSAIDs in inﬂammatory rheumatic diseases led to a 40%
reduction in the need for concomitant oral NSAIDs, with a
signiﬁcant reduction in the reporting of GI AEs [58]. Studies of
patient preference showed that 75% of patients would choose to
use a topical NSAID in preference to an oral NSAID [57].
For considerations of safety, topical NSAIDs may be used in
preference to oral NSAIDs due to their lower systemic absorption
and consequent better tolerability proﬁle. Topical NSAIDs may be
considered as the preferred treatment option, particularly in OA
patients aged 75 years or older, and those with co-morbidities, or
those at an increased risk of GI, cardiovascular (CV), or renal side
effects.Step 2: Advanced pharmacological treatment
Oral NSAIDs
If Step 1 treatments show inadequate efﬁcacy and the patient is
still symptomatic, or in patients presenting with moderate-severe
pain, beneﬁt may be obtained with advanced pharmacological
treatments. Oral NSAIDs traditionally play a central role in the
pharmacological management of OA. Oral NSAIDs have a moderate
effect on pain relief, with effect size of 0.29 (95% CI: 0.22–0.35)
that is greater than that of paracetamol (ES ¼ 0.14) [14], and with
demonstrated greater efﬁcacy in patients with more severe OA
accompanied by a higher degree of patient preference [59].
Cyclooxygenase-2 (COX-2) selective, partially selective, or non-
selective NSAIDs are shown to be similarly effective in controlling
pain [47]. In recent years, the widespread use of NSAIDs has been
questioned due to the reporting of signiﬁcant upper GI complica-
tions (UGIC) and CV AEs [9].
Oral NSAIDs are associated with a three- to ﬁve-fold increase in
the risk of UGIC, including peptic ulcer perforation, obstruction,
and bleeding [60,61]. However, there is considerable variability in
UGIC and CV risk for individual NSAIDs [62,63]. The high risk of
UGIC with indomethacin was attenuated by use of acemetacin, a
prodrug, which is less active on the COX-1 enzyme in the gastric
mucosa, resulting in a reduction in GI AEs of around one-third
[64]. Celecoxib and ibuprofen have a low relative risk for UGIC
compared with other NSAIDs [65], while nabumetone is associated
with 10-fold fewer GI AEs than other NSAIDs [66,67].
The use of gastroprotective agents such as proton pump
inhibitors (PPIs) can reduce the occurrence of UGIC by 50–60%
[68]. While COX-2 selective inhibitors are associated with a lower
risk of UGIC compared with non-selective NSAIDs, there is still a
signiﬁcant increase in risk compared with placebo [69]. The ESCEO
task force recommends that in patients with low (normal) GI risk,
it should be considered to prescribe either a non-selective NSAID
with or without a PPI or a COX-2 selective NSAID based on the
judgement of the clinician (Fig.) [5].
The choice of which NSAID to use in clinical practice depends
on individual patient characteristics and medical history [5]. The
ESCEO task force recommends that patients are assessed for risk
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making treatment decisions. Several patient factors have been
identiﬁed to increase the risk of UGIC, including advanced age, a
history of GI ulcer, and concomitant treatment with corticoste-
roids, aspirin, or anticoagulants [62,70]. In patients with high GI
risk, which includes patients receiving concomitant low-dose
aspirin, non-selective NSAIDs should be avoided and COX-2
selective NSAIDs should be co-prescribed with a PPI [71]. Patient
preference is an important consideration, for example, of dosing
regimen whether once daily or more frequent dosing is desirable.
There is little doubt that all oral NSAIDs, selective and non-
selective, increase the risk of serious CV events [69] and should be
avoided in high CV risk patients. Ibuprofen should not be used
with concomitant low-dose aspirin due to clinically relevant
pharmacological interaction [72]. Naproxen is the exception, and
may be the preferred agent if an NSAID is required in patients at
high CV risk, because of its lower risk of CV events [69,73], which
may be due to its sustained suppression of platelet aggregation
[69]. In patients with increased renal risk, such as chronic
kidney disease with estimated GFR below 30 cc/min, the ESCEO
task force recommends that oral NSAID use is avoided [5].
The ESCEO task force recommends that oral NSAIDs may be
used intermittently or continuously in longer cycles rather than in
chronic use, at the lowest effective dose and for the shortest time
necessary to control symptoms, because of safety concerns and a
lack of long-term trials [1]. In the event of insufﬁcient control of
symptoms with an NSAID, the combination of NSAIDs is not
recommended by the ESCEO task force, as there is no evidence
of additional beneﬁt, and an increased risk of AEs, with additional
cost of treatment. While switching NSAIDs may provide some
beneﬁt, the ESCEO task force does not recommend multiple
successive rounds of NSAIDs before considering other treatment
options. In the case of contraindications to NSAIDs, or if the patient
is still symptomatic despite use of NSAIDs, intra-articular treat-
ment may be considered (Fig.) [1].
Hyaluronic acid
Viscosupplementation with intra-articular (IA) hyaluronic acid
(HA) is an effective treatment for knee OA with beneﬁcial effects
on pain, function, and patient global assessment [74]. There is good
evidence for the effectiveness of HA from RCTs, with a high effect
size of 0.63 when compared with oral placebo, found in a recent
network meta-analysis [75]. IA HA was the most efﬁcacious treat-
ment for pain among all OA interventions. However, the IA
delivery method itself had a signiﬁcant effect size of 0.29 com-
pared with oral placebo. This might be explained by the fact that
injecting any ﬂuid in the joint could potentially inﬂuence noci-
ceptive response by affecting the peripheral nervous system. More
importantly, when ﬂuid is aspirated prior to HA injection, such a
procedure might exert a mild anti-inﬂammatory effect by remov-
ing inﬂammatory cytokines or pain-modulating neuropeptides
and other mediators [76]. Despite this, when compared with IA
placebo, a statistically signiﬁcant effect size of 0.34 [95% credible
interval (CrI): 0.26–0.42] was shown for IA HA on pain at 3 months
[75]. In trials directly comparing IA HAwith continuous oral NSAID
treatment, the effect size of IA HA on pain was not signiﬁcantly
different to that of NSAIDs up to 12 weeks [77]. IA HA demon-
strated a more favorable safety proﬁle, with injection site pain as
the most common AE, compared with more frequent GI AEs with
NSAID therapy. In this respect, IA HA may be a good alternative to
NSAIDs for knee OA, especially for older patients or in those at
greater risk for NSAID-induced AEs.
HA is not a rapidly acting agent, but rather the clinical effect on
pain and function extends for a long time after administration, up
to 6 months post-injection [78]. Analysis of US-approved IA HAinjections found a signiﬁcantly large treatment effect from 4 weeks
up to 26 weeks for knee pain (SMD ¼ 0.38) and knee function
(SMD ¼ 0.32) compared with placebo (p o 0.001) [78]. HA has a
slow onset of action, with efﬁcacy demonstrated by week 4,
reaching a peak at 8 weeks that is maintained for up to 6 months
[79]. In comparison, IA corticosteroids provide greater pain relief
in the short-term up to 4 weeks, while beyond 8-weeks post-
injection IA HA demonstrates superior, longer-lasting efﬁcacy [80].
Real-life evidence for the long-term effectiveness of IA HA is
reported in a study of over 300 patients with knee OA who
received repeat cycles of IA HA injections (4 cycles of 5 weekly
injections) [81]. After 40 months (12 months after the last treat-
ment cycle), signiﬁcantly more treatment responders were found
in the treatment group compared with placebo according to OARSI
2004 criteria for pain, function, and patient global assessment
(80.5% of responders with HA vs. 65.8% for placebo; p ¼ 0.004)
[81]. Notably, the number of responders to IA HA increased
progressively after each treatment cycle, while response to placebo
remained fairly stable. In other observational studies, IA HA
injections in knee OA were highly effective in improving resting
and walking pain with duration of symptom control up to
6 months, and a reduction in concomitant analgesia use of
30–50%. Few AEs were reported, mostly limited to mild or
moderate local AEs of transient pain and swelling [82–84].
Furthermore, IA HA delayed the need for total knee replacement
(TKR) surgery by approximately 2 years [85–87].
Most head-to-head clinical trials performed to date have found
non-inferiority with respect to symptomatic efﬁcacy between the
HA preparations of various molecular weights (MWs) tested [88–92].
In a head-to-head clinical trial of intermediate MW HA vs. low MW
HA, the intermediate MW HA provided statistically superior pain
relief at 6 months (p ¼ 0.021) [93]. Cross-linked high MW HAs
(hylans) have comparable efﬁcacy with intermediate MW HA [94],
but are associated with increased safety concerns due to an
increased rate of ﬂares/non-septic post-injection arthritis [95];
hylans are twice as likely to cause local adverse reactions
(RR ¼ 1.91; 95% CI: 1.04–3.49; I2 ¼ 28%) and ﬂares (RR ¼ 2.04;
95% CI: 1.18–3.53; I2 ¼ 0%) compared with intermediate or low MW
HA [94].
Although the exact mechanism of action of exogenous HA is
unknown, the proposed mechanism occurs in 2 stages, a mechan-
ical stage and a pharmacological stage [80,96]. Injection of a high
concentration of HA provides viscosupplementation [97,98], while
the induction of biosynthesis of endogenous HA and extracellular
matrix components [99] can occur, which reduces proteoglycan
loss in cartilage and apoptosis of chondrocytes [97,100]. The
endogenous synthesis of HA by synovial ﬁbroblasts is inﬂuenced
by the concentration and MW of HA in the extracellular environ-
ment [99,101]. The optimal stimulation of HA biosynthesis occurs
with intermediate MW HA binding to synovial ﬁbroblast cell
receptors; this binding may be limited by the steric volume of
high MW HA, and only weak binding occurs with low MW HA
[99]. The re-establishment of joint homeostasis through induction
of endogenous HA production continues long after the exogenous
injection has left the joint.
While further investigation into the OA patient types most
likely to beneﬁt from IA HA is warranted, the ESCEO task force
recommends the use of IA HA in knee OA patients with mild-
moderate disease, and for more severe patients who are either
contraindicated to TKR surgery or wishing to delay the surgical
procedure. IA HA should only be administered in knee OA once the
acute inﬂammatory ﬂare has settled. In these patients, IA cortico-
steroids may be used ﬁrst line to treat the knee effusion. In
this respect, it is useful to note that the combination of
HA and IA corticosteroids could be contraindicated due to
some meddling effects between them, unless pharmaceutical
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treatment effect of IA HA is comparable with NSAIDs, IA HA is
positioned later in the treatment algorithm, unless NSAIDs are
contraindicated, due to the requirement for repeat injections
usually performed by a trained, specialized practitioner (either
rheumatologist or orthopedic surgeon). Nonetheless, IA HA is an
effective and safe treatment for long-term management of knee
OA and may be a cost-effective treatment (to be further studied).Step 3: Last pharmacological treatment
Last pharmacological options for the severely symptomatic
patient may be represented by the use of short-term weak opioids.
Opioids, in general, are associated with signiﬁcant morbidity [102].
Conventional opioid analgesics may cause respiratory depression,
dependence, and have the potential for drug abuse. However,
weak opioids such as tramadol offer good analgesia with improved
safety proﬁle. Antidepressants, including duloxetine, have been
used in chronic pain syndromes because they act centrally to alter
pain neurotransmitters (serotonin and norepinephrine) and scant
evidence of an effect is shown in OA albeit with a high rate of AEs
[103,104]. Tramadol and duloxetine should not be used in combi-
nation, due to the overlapping mechanisms of action on central
pain neurotransmitters.
Tramadol
Tramadol is a weak opioid that has small but signiﬁcant efﬁcacy
for the relief of pain and improvement of function in knee OA
[105]. Treatment of knee OA with short-term tramadol has been
shown to reduce pain, reduce stiffness, and improve function and
overall well-being, with signiﬁcant results for patients’ overall
assessment of therapy compared with placebo [105,106].
Tramadol is a synthetic, centrally acting opioid agonist that acts
through both weak opioid and non-opioid mechanisms [107].
Consequently, tramadol rarely causes the AEs of respiratory
depression and physical dependence commonly associated with
conventional opioid drugs. Tramadol use is also not associated
with the GI and CV AEs attributed to NSAIDs [105]. The most
frequently reported AEs with tramadol are nausea and headache,
which may result in treatment withdrawal and sub-optimal pain
management [108,109].
Sustained-release (SR) formulations may improve tramadol
tolerability and reduce the incidence of AEs [110]. SR formulations
of tramadol are associated with prolonged effective plasma levels
of tramadol, while preventing the high plasma peaks associated
with AEs with the immediate-release formulations [110,111]. The
risk of AEs may be further attenuated by the slow upward titration
of tramadol SR from 50 to 100 mg bid over 7 days, which affords a
reduction in AEs and reduced frequency of treatment discontinua-
tions [112].
The short-term use of tramadol may be considered for severely
symptomatic OA patients and there is good evidence that tramadol
works if prescribed properly. The SR formulation of tramadol is
preferred and the slow upwards titration of tramadol SR is
recommended to improve tolerability and minimize AE-related
treatment discontinuations.Conclusions
Few clinical trials have been designed to study the effect of
given treatment in patients in whom initial therapies have failed,
and/or when and how new treatments should be introduced.
However, the assessment of the evidence base by the internationalESCEO task force has provided a stepwise multi-modal treatment
algorithm for the practical management of knee OA [5]. Recent
real-life studies provide additional evidence in support of phar-
macological interventions, in terms of management of OA pain and
function, avoidance of AEs, disease-modifying effects and long-
term outcomes, e.g., delay of TKR surgery, and pharmacoeconomic
factors such as reduction in healthcare resource utilization.
In clinical practice, treatment should be based upon the
individualized assessment of the patient, taking into account a
patient’s needs and preferences, or the subjective interpretation of
the evidence by the physician. In the future, identiﬁcation of
patient proﬁles may lead to more personalized healthcare, with
more targeted treatment for OA [113]. For now, this stepwise
approach to the pharmacological management of knee OA is
advocated by the ESCEO task force. During step 1, background
treatment with SYSADOAs using only the prescription formula-
tions of pCGS or CS is recommended, with paracetamol as add-on
rescue analgesia for short-term therapy. Topical NSAIDs may be
included for additional analgesia given that their symptomatic
efﬁcacy is similar to the oral NSAIDs but with superior systemic
safety. Oral NSAIDs maintain a central role in the step 2 advanced
pharmacological management of the persistently symptomatic
patient. NSAIDs as a class, including non-selective and COX-2
selective NSAIDs, are heterogeneous and there is wide disparity
in the AE risk for GI and CV events between different oral NSAIDs.
Patient stratiﬁcation and careful selection of appropriate medica-
tion can help to minimize risks while maintaining clinical beneﬁt
of treatment. Intra-articular treatment represents the next stage in
the stepwise treatment algorithm, for patients who fail to derive
sufﬁcient symptomatic beneﬁt from prior treatments. IA HA can be
clearly differentiated from IA corticosteroids by the duration of the
induced beneﬁt, lasting for up to 6 months after a short weekly
injection course. Step 3 comprises the last pharmacological
attempt before surgery and includes short-term weak opioids,
such as tramadol. SR formulation and dose titration of tramadol
can help to limit the side effects often associated with opioid
treatment, and minimize treatment discontinuations while pro-
viding sustained efﬁcacy.
Overall, this guidance provides evidence-based and easy-to-
follow advice on how to establish a treatment ﬂow in patients
with knee OA, for practical implementation in real-world clinical
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